DENZA
26.12.2023 05:17:36 CET | Business Wire | Press release
As a luxury new energy brand co-created by BYD, a leader in new energy vehicles, and Mercedes-Benz, the inventor of the gasoline car, DENZA has globalization in its DNA. Not only are all its products designed for a global audience, but it also aspires to be a leading global new energy luxury car brand. Guided by a global strategy, DENZA actively embraces and implements the "Belt and Road" initiative, building a global brand image, honing its internal strengths, and achieving remarkable success both domestically and internationally.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20231225949027/en/
DENZA D9 at the Bangkok International Motor Show (Photo: Business Wire)
2023 marks DENZA's inaugural year on the international stage, with significant appearances at top global auto shows, such as the Bangkok International Motor Show in March, visited by former Prime Minister Prayut Chan-o-cha; the Munich International Motor Show in September, where its European debut was widely acclaimed; the Japan Mobility Show in October, where it stood out as the sole Chinese luxury car brand and secured its first international order; the Thailand International Motor Expo in November, where the DENZA N7 continued its international journey following the DENZA D9; and the Hong Kong International Auto Show in December, where the DENZA D9 made its debut and opened for pre-orders. With a steady and orderly international expansion, DENZA has not only won the hearts of global media and customers but has also laid a solid foundation for becoming a leading international high-end brand, poised to be the "business card" of Chinese new energy luxury cars, redefining China's automotive industry and introducing DENZA to a global audience.
Beyond its international success, DENZA has also achieved remarkable results in the domestic market. Its first MPV, the DENZA D9, with its luxurious features in design, comfort, intelligence, control, and safety, and its suitability for both family and business use, became the fastest Chinese new energy luxury model to deliver 100,000 units in just 11 months, setting a new industry record. As of early December 2023, the DENZA D9 has been the top-selling luxury MPV over RMB 300,000 for 11 consecutive months and is expected to be the annual sales champion for MPVs in 2023.
Notably, the DENZA D9 excels in both sales volume and pricing, boasting an average selling price exceeding RMB 420,000, making it the highest-priced model among Chinese automotive brands. Additionally, it holds the top position in resale value within the new energy MPV segment after one year, setting a new standard in the luxury MPV market. Beyond its popularity among mainstream families, the DENZA D9 is the vehicle of choice for many modern elites, including national actress Hai Qing, famous TV host Yang Lan, and prominent entrepreneur Cao Hui, all embracing this new luxury.
As a pioneer combining BYD's leading new energy technology and Mercedes-Benz's luxury manufacturing heritage, each step in DENZA's global journey not only opens infinite possibilities for the brand but also showcases the charm and strength of Chinese new energy luxury car brands. In the future, DENZA will continue to accelerate its global development, enrich its luxury product lineup, and create an unparalleled luxury travel experience for global users, further supporting China's journey towards becoming an automotive powerhouse.
About DENZA
In 2010, DENZA, a luxury new energy car brand, was jointly established in Shenzhen by BYD, a leader in new energy vehicles, and Mercedes-Benz, the inventor of the gasoline car. It was the first brand dedicated to the new energy luxury car market. Over the past thirteen years, DENZA has gone through three phases: initiation, accumulation, and innovation. Meanwhile, the Chinese market has witnessed a wave of technological revolution in new energy vehicles, rapidly changing people’s understanding of cars and significantly transforming the luxury car market with the development of new energy. On May 16, 2022, DENZA underwent a brand renewal, embodying three distinct attributes and three leading advantages from the outset. We possess an independent brand, products, and team, and have three core competitive advantages in our products and services. First is the leading new energy and intelligent technology endowed by the BYD Group; second is the leading luxury product quality resulting from thirteen years of joint development with Mercedes-Benz; third is the soft power that DENZA has built to meet the current and future needs of new energy vehicle users – a leading user ecosystem service system. In the future, we aim to create a new luxury and comprehensive travel experience for our users and build a more valuable smart and safe new luxury car brand.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20231225949027/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom